Nanovibronix (NASDAQ:FEED) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Nanovibronix (NASDAQ:FEED) from a hold rating to a sell rating in a report published on Saturday.

Separately, Weiss Ratings initiated coverage on shares of Nanovibronix in a report on Tuesday, January 27th. They issued a “sell (e+)” rating on the stock. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Nanovibronix Price Performance

Nanovibronix stock opened at $1.93 on Friday. Nanovibronix has a 52-week low of $0.99 and a 52-week high of $162.50. The firm has a market cap of $2.10 million, a price-to-earnings ratio of -0.05 and a beta of 2.26.

Insider Activity at Nanovibronix

In other Nanovibronix news, major shareholder Christian Michael Glibert purchased 240,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 14th. The shares were acquired at an average cost of $2.67 per share, for a total transaction of $640,800.00. Following the transaction, the insider directly owned 240,000 shares in the company, valued at approximately $640,800. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 5.20% of the stock is owned by insiders.

Nanovibronix Company Profile

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.